Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study

Adding atezolizumab to a combination of bevacizumab, carboplatin and paclitaxel gives patients with metastatic nonsquamous non-small-cell lung cancer better odds of progression-free and overall survival, a new study of 692 patients with wild-type disease has concluded.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news

Related Links:

Recent clinical trials have put immunotherapy front and center for initial treatment decisions in advanced lung cancer.Journal of Clinical Oncology
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Hematology-Oncology Journal Article Source Type: news
Authors: Debieuvre D, Moreau L, Coudert M, Locher C, Asselain B, Coëtmeur D, Dayen C, Goupil F, Martin F, Brun P, De Faverges G, Hauss PA, Gally S, Ben Hadj Yahia B, Grivaux M Abstract INTRODUCTION: The benefit of tyrosine kinase inhibitors for patients with an EGFR wild-type non-small cell lung cancer (NSCLC) remains controversial. METHODS: The survival of patients with an EGFR wild-type NSCLC who received second- or third-line erlotinib treatment was assessed using real-life data that had been collected in a prospective, national, multicenter, non-interventional cohort study. RESULTS: Data from 274 p...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Authors: Rouviere D, Veillon R, Chaltiel L, Simonneau Y, Filleron T, Milia J, Guibert N, Melloni B, Raherisson C, Didier A, Mazieres J Abstract The central nervous system (CNS), through carcinomatous meningitis or solid brain metastases, is the most common site of recurrence in non-small cell lung cancers (NSCLC) with activating mutations. Our retrospective study describes the population of patients with CNS metastases of NSCLC harboring activating mutation with targeted therapy (EGFR, ALK, BRAF, HER2) in 4 French regional reference hospitals. 60 patients were analyzed. The proposed treatments were heterogeneous an...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Authors: Ewig S, Larrosa-Lombardi S, Halboos A, Hecker E Abstract Surgical resection continues to be a mainstay of curative treatment of patients with non-small cell lung cancers stages I - III and some small cell lung cancers. Reported rates of complications and mortality vary considerably. Therefore, a thorough and comprehensive preoperative evaluation of lung cancer patients is crucial in order to select appropriate surgical candidates and to determine their individual risk, including the extent of resection possible. Following available data and guidelines, such evaluation should include: ECOG-scoring, card...
Source: Pneumologie - Category: Respiratory Medicine Tags: Pneumologie Source Type: research
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non - small cell lung cancer
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news
Conclusion: Trained dogs were able to identify non-small cell lung cancer samples from healthy controls. The findings of this study provide a starting point for a larger-scale research project designed to explore the use of canine scent detection as a tool for cancer biomarkers. PMID: 31206136 [PubMed - as supplied by publisher]
Source: Journal of the American Osteopathic Association - Category: Complementary Medicine Tags: J Am Osteopath Assoc Source Type: research
In this study, we developed GRPs from the two NSCLC cell lines PC9 and HCC827, which express an EGFR exon 19 deletion mutation, by treatment with a high concentration of gefitinib. The GRPs from both PC9 and HCC827 cells expressed high levels of CD133 and FBXW7, but low levels of c-MYC. Cell cycle analysis demonstrated that the majority of GRPs existed in the G0/G1 phase. Knockdown of the FBXW7 gene significantly reduced the cell number of CD133-positive GRPs and reversed the cell population in the G0/G1-phase. We also found that FBXW7 expression in CD133-positive cells was increased and c-MYC expression was decreased in g...
Source: Bosnian Journal of Basic Medical Sciences - Category: General Medicine Tags: Bosn J Basic Med Sci Source Type: research
TUESDAY, June 18, 2019 -- The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue of the...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
AbstractBackground.Tissue tumor mutational burden (TMB) has emerged as a potential biomarker predicting response to anti‐programmed cell death‐1 protein receptor (PD‐1)/programmed cell death‐1 protein ligand (PD‐L1) therapy, but few studies have explored using circulating tumor DNA (ctDNA) TMB in non‐small cell lung cancer (NSCLC).Materials and Methods.A total of 136 patients with NSCLC with ctDNA testing were retrospectively evaluated from a single institution, along with a validation cohort from a second institution. ctDNA TMB was derived using the number of detected mutations over the DNA sequencing length.R...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Precision Medicine Clinic: Molecular Tumor Board Immuno ‐ Oncology Source Type: research
Conclusion.Receiving radiation prior to starting osimertinib for patients with progressing brain metastases did not prolong TTF, PFS, or OS in our series. To minimize the risks of radiation‐related toxicity, delaying radiation could be considered for some patients with EGFR‐mutant NSCLC with brain metastases who initially respond to osimertinib in the second‐line setting.Implications for Practice.Osimertinib is a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor recently approved for the first‐line treatment of EGFR‐mutant non‐small cell lung cancer. Although it appears to hav...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Health | Lung Cancer | Non-Small Cell Lung Cancer | Study